GlassScriptPhysician profile
Michael R Gabbard
NPI 1407294481
$1,051.86
in general payments reported to CMS, 2019-2025
18 companies · $232 in 2025
The $232 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $201 · 2020: $11.56 · 2021: $28.42 · 2022: $105 · 2023: $282 · 2024: $193 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $674 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $673.53 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $264.36 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $136.80 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $124.74 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $106.52 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $79.67 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $53.29 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $47.18 | 2023-2024 | |
| Sunovion Pharmaceuticals INC. | $38.52 | 2022 | |
| Abbott Laboratories | $30.81 | 2021-2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $27.83 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.20 | 2019-2023 | Jardiance |
| Axsome Therapeutics, INC. | $26.51 | 2023 | Auvelity |
| Dexcom, INC. | $18.02 | 2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $17.76 | 2025 | Gemtesa |
| Astellas Pharma US INC | $15.44 | 2023 | Veozah |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $13.05 | 2022 | |
| Phathom Pharmaceuticals, INC. | $12.10 | 2025 | Voquezna |
| Pfizer INC. | $12.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gabbard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.